Four phthalazinones (CIDs 22334057, 22333974, 22334032, 22334012) and one isoquinolone (CID 5224943) were previously shown to be potent enhancers of antifungal activity of fluconazole against Candida albicans. Several even more potent analogues of these compounds were identified, some with EC50 as low as 1 nM, against C. albicans. The compounds exhibited pharmacological synergy (FIC < 0.5) with fluconazole. The compounds were also shown to enhance the antifungal activity of isavuconazole, a recently FDA approved azole antifungal. Isoquinolone 15 and phthalazinone 24 were shown to be active against several resistant clinical isolates of C. albicans
Increasing resistance against antimycotic drugs challenges anti‐infective therapies today and contri...
Background: Candidasis is one of the most commonly encountered human fungal infections and is caused...
Candidiasis, caused by the opportunistic yeast Candida albicans, is the most common fungal infection...
Azoles are antifungal drugs used to treat fungal infections such as candidiasis in humans. Their ext...
Several azoles are widely used to treat human fungal infections. Increasing resistance to these azol...
International audienceWe identified a new series of azole antifungal agents bearing a pyrrolotriazin...
Objectives: In this study we investigated the in vitro fungistatic and fungicidal activities of CPA1...
We previously reported the antifungal properties of a monoterpene phenol "Eugenol" against different...
We previously reported the antifungal properties of a monoterpene phenol "Eugenol" against different...
Cyclohexyliden- and 2-methylcyclohexyliden-hydrazo-4-arylthiazoles were synthesized and tested as an...
DU-6859a is an investigational fluoroquinolone agent with potent bactericidal activity, but by itsel...
The clinical prevalence of antifungal drug resistance has been increasing over recent years, resulti...
The in vitro antifungal activity of D0870 against eight isolates of fluconazole-resistant Candida al...
The increased resistance of Candida albicans to conventional antifungal drugs poses a huge challenge...
Fungal infections are rising, with over 1.5 billion cases and more than 1 million deaths recorded ea...
Increasing resistance against antimycotic drugs challenges anti‐infective therapies today and contri...
Background: Candidasis is one of the most commonly encountered human fungal infections and is caused...
Candidiasis, caused by the opportunistic yeast Candida albicans, is the most common fungal infection...
Azoles are antifungal drugs used to treat fungal infections such as candidiasis in humans. Their ext...
Several azoles are widely used to treat human fungal infections. Increasing resistance to these azol...
International audienceWe identified a new series of azole antifungal agents bearing a pyrrolotriazin...
Objectives: In this study we investigated the in vitro fungistatic and fungicidal activities of CPA1...
We previously reported the antifungal properties of a monoterpene phenol "Eugenol" against different...
We previously reported the antifungal properties of a monoterpene phenol "Eugenol" against different...
Cyclohexyliden- and 2-methylcyclohexyliden-hydrazo-4-arylthiazoles were synthesized and tested as an...
DU-6859a is an investigational fluoroquinolone agent with potent bactericidal activity, but by itsel...
The clinical prevalence of antifungal drug resistance has been increasing over recent years, resulti...
The in vitro antifungal activity of D0870 against eight isolates of fluconazole-resistant Candida al...
The increased resistance of Candida albicans to conventional antifungal drugs poses a huge challenge...
Fungal infections are rising, with over 1.5 billion cases and more than 1 million deaths recorded ea...
Increasing resistance against antimycotic drugs challenges anti‐infective therapies today and contri...
Background: Candidasis is one of the most commonly encountered human fungal infections and is caused...
Candidiasis, caused by the opportunistic yeast Candida albicans, is the most common fungal infection...